<b>Conclusions:</b> In patients with T2D and established ASCVD, GLP-1RA use was more strongly associated with the intensity of glucose-lowering therapy-particularly insulin use-than with cardiovascular or renal risk profiles. This evidence concerns the gene INS and type 2 diabetes mellitus.